Home
overview
The demand for non/minimally invasive diagnostics is expanding the market for such products rapidly. The market drivers are patients, who are benefiting from the use of these diagnostics with shorter hospital stays and increased comfort and healthcare providers who can dramatically cut costs with more efficient diagnostic methods. This expansion has been coupled with rapidly advancing technologies as more companies enter this competitive market.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s Strategies in the Non/Minimally Invasive Diagnostic Market. As you will see from the brochure, key speakers in the diagnostic industry will focus on strategic issues in today’s diagnostics market, from technological advances to strategic issues.

Our programme includes: (a) Case studies on collaborations between pharmaceutical companies and diagnostics companies. (b) A range of critical issues including: the up coming European IVD Directive, strategic partnering and acquisitions and marketing to different consumer groups. (c) Practical workshops on ‘Strategic Planning for a Successful In Vitro Diagnostics Portfolio’ and ‘Regulatory and Reimbursement Strategies in the Diagnostics Industry’

Strategies in the Non/Minimally Invasive Diagnostic Market is organised and produced by SMi. We specialise in providing senior executives with timely, strategic and focused pharmaceutical business information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions.

Conference programme

8:30 Registration and Coffee

9:00 Chairman’s opening remarks

John Place

John Place, Director General, European Diagnostic Manufacturers Association

9:10 EXPECTATIONS FOR MODERN DIAGNOSTICS

Alex Grant

Alex Grant, Managing Director, Roche Diagnostics

  • Issues for developing modern diagnostics
  • Considering patients as consumers
  • Increased efficiency
  • Improved outcomes
  • Improving cost effectiveness of healthcare
  • Strategic marketing of diagnostic products
  • 9:40 EUROPEAN REGULATORY ISSUES

    Terry Donohoe

    Terry Donohoe, Technical Manager, Sterile, Surgical and In Vitro Diagnostic Devices, Medical Device Agency

  • What are the medical device directives?
  • What does each one cover?
  • What will they mean for me?
  • 10:20 GLOBAL REGULATIONS

    Bev Davis

    Bev Davis, Manager, Regulatory Affairs, Ortho-Clinical Diagnostics

  • Diversity of global regulations for in vitro diagnostics
  • Necessity of working in collaboration with regulatory authorities
  • Understanding the worldwide regulations
  • Speeding up the approvals process
  • Using established standards to your advantage
  • Input to product development process
    Benefits of good presentation and consistency
  • 11:00 Morning Coffee

    11:20 THE PARADIGM SHIFT IN MEDICAL DIAGNOSIS AND TREATMENT

    Prof Dr Uwe Bicker

    Prof Dr Uwe Bicker, Executive Chairman and Director, Dade Behring

  • From phenotype to genotype
  • Industry focus on cross cutting research and technologies
  • Increased role of testing in therapeutic decisions
  • Testing and monitoring for cost effective treatment
  • Future outlook
  • 12:00 STRATEGIC PARTNERING

    Keith Ignotz

    Keith Ignotz, President and Chief Operating Officer, SpectRx

  • Acquisition vs partnership: why choose partnership?
  • Choosing the right partners to meet your needs
  • Advantages to both parties:
  • Increased research funds
  • Sharing of knowledge/expertise
  • Distribution and marketing possibilities between two companies
  • 12:40 Lunch

    14:00 GENENTECH AND DAKO: SUCCESSFUL COLLABORATORS

    Dr Sven Godtfredsen

    Dr Sven Godtfredsen, Vice President of Corporate Research, DAKO

  • Sharing expertise to benefit both parties
  • The benefits of licensing patent rights to diagnostic companies
  • Value of collaboration to diagnostic companies: reducing RandD time and expenditure
  • Developing the collaboration further
  • Simultaneous marketing of diagnostics and therapeutics
  • 14:40 MERGERS AND ACQUISITIONS

    Alex Watson

    Alex Watson, Managing Director, Watson Biomedical

  • Evolution
  • Consolidation drivers
  • The strategic fit
  • Company ethos
  • At what price?
  • Market reaction
    The future industry structure
  • 15:20 Afternoon Tea

    15:40 COST EFFECTIVENESS OF CENTRALISED LABORATORY TESTING

    Kerry Bush

    Kerry Bush, President and Chief Operating Officer, Meretek

  • Principles of breath testing
  • The Urea breath Test (UBT) for detection of H.pylori
  • Cost effectiveness and medical economics of the UBT
  • Regulatory issues
  • Manufacturer to user: the economic equation
    Laboratory testing: centralised and Point of Care
  • Future Developments in the breath test platform
  • 16:20 MARKETING POINT OF CARE DIAGNOSTICS TO HEALTHCARE PROFESSIONALS

    Conor McGurk

    Conor McGurk, Managing Director, Cardiac Services Diagnostics

  • Potential of POC diagnostics
  • Pharmacoeconomic evaluation of POC diagnostics as a marketing tool
  • Expectations of healthcare professionals
  • Ease of use
  • Reliability
  • Favourable comparisons to existing diagnostics
    Where, when and how to market to health care providers
  • 17:00 Chairman's closing remarks and close of day one

    17:10 Informal networking drinks reception for delegates and speakers

    8:30 Re-registration and coffee

    9:00 Chairman's Opening Remarks

    Kit Madden OBE

    Kit Madden OBE, President, British In Vitro Diagnostic Association

    9:10 BETTER, FASTER, SMALLER: FUTURE OF DIAGNOSTIC ASSAYS

    Thomas Gutshall

    Thomas Gutshall, Chief Executive Officer, Cepheid

  • Advantages of point of care diagnostics
  • Economic advantages to health care providers of point of care diagnostics
  • I-CoreTM and MicroBETM: in the field analysis
  • Use of I-CoreTM and MicroBETM in diagnostics
  • Future potential of miniaturisation
  • 9:40 MINIMALLY INVASIVE GENETIC DIAGNOSTICS

    Dr Stephen Little,

    Dr Stephen Little,, Research and Development Manager, AstraZeneca Diagnostics

  • Genetics in Human Disease
  • Genotyping using non/minimally invasive techniques
  • Applications of genetic diagnostics:
  • Predisposition testing
  • Early detection
  • Pharmacogenetics and therapy selection

    The future of gene based diagnostics

  • 10:20 TECHNOLOGY: DIFFERING APPROACHES TO CANCER DIAGNOSTICS

    Frank Castellana

    Frank Castellana, Acting President, Mediscience Technology

  • Introduction to the principles of light spectroscopy
  • Applications and advantages in cancer detection
  • Product specifications and performance characteristics
  • Clinical trial protocols
  • Other clinical applications
  • 11:00 Morning coffee

    11:20 IMPROVEMENTS IN CANCER DIAGNOSIS

    Stanley Lapidus

    Stanley Lapidus, Chief Executive Officer, EXACT Laboratories

  • Current methods for early cancer diagnosis
  • Improving prognosis by early detection
  • DNA based stool diagnosis
  • Diagnostic tools to aide in therapeutic research
  • Partnerships and collaborations
  • Future prospects
  • 12:00 THE BENEFITS OF IMMUNOASSAY

    Elizabeth Somers

    Elizabeth Somers, Marketing Manager, Fujirebio Diagnostics

  • Current methods of diagnosing cancer
  • Impact of early diagnosis on patient prognosis
  • Decreased costs of diagnosis using tumour markers combined with imaging
  • Raising product profile amongst health care professionals
  • Potential of immunoassay diagnostics
  • Impact of early diagnosis on patient prognosis
  • 12:40 Lunch

    14:00 EARLY DIAGNOSIS FOR REPRODUCTION CANCERS

    Patrick Walch

    Patrick Walch, CEO, Atairgin Technologies

  • Early detection of ovarian cancer
  • Value in outcomes
  • Role of LPA as a diagnostic tool
  • Role of lipids in breast cancer detection
  • 14:40 PATIENT INITIATED DIAGNOSTIC SERVICES

    Dr Paul Debenham

    Dr Paul Debenham, Director, Life Sciences, LGC

  • Sampling methods
  • Establishing the market
  • Follow up/counselling for consumers
  • Confidentiality: involving the GP
  • Lessons to be learned for other direct to patient services
  • 15:20 Afternoon tea

    15:40 RISK STRATIFICATION AND DIAGNOSTIC TOOLS

    Dr William DeLorbe

    Dr William DeLorbe, Executive Vice President of Medical Imaging, DuPont Pharmaceuticals

  • Defining risk stratification
  • Potential of risk stratification diagnostics in the healthcare industry
  • Cost effective
  • Better outcomes
  • Potential therapeutic areas which would benefit from risk stratification
  • Pricing and marketing issues for ‘at risk’ diagnostics
  • 16:20 SELLING DIRECT TO EMPLOYERS

    Joanne Grigg

    Joanne Grigg, Product Manager, B M Browne UK

  • Why drugs test
  • Principles of rapid vs laboratory testing
  • Find the right markets to target
  • Ethical considerations and legal viewpoint
  • Ensuring the right customer information
  • Pricing issues for drug tests
    Potential future for OTC diagnostic kits
  • 17:00 Chairman's closing remarks and close of conference

    +

    Workshops

    Strategic Planning for a Successful In Vitro Diagnostics portfolio
    Workshop

    Strategic Planning for a Successful In Vitro Diagnostics portfolio

    The Hatton, at etc. venues
    8th December 1999
    London, United Kingdom

    Regulatory and Reimbursement Strategies in the Diagnostics Industry
    Workshop

    Regulatory and Reimbursement Strategies in the Diagnostics Industry

    The Hatton, at etc. venues
    8th December 1999
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.